132 related articles for article (PubMed ID: 38296626)
1. [Establishment of a 21-color Panel for the Detection of Immune Cell Subsets
in Human Non-small Cell Lung Cancer Tumor Tissues with Flow Cytometry].
Guo T; Xie H
Zhongguo Fei Ai Za Zhi; 2024 Jan; 27(1):56-64. PubMed ID: 38296626
[TBL] [Abstract][Full Text] [Related]
2. [Establishment of 14-Color Panel for Determining Leukocyte Subsets in Human Peripheral Blood with Flow Cytometry].
Huang QR; Jiang YN; Li HF; Li X; Meng WT
Sichuan Da Xue Xue Bao Yi Xue Ban; 2022 Jan; 53(1):127-132. PubMed ID: 35048612
[TBL] [Abstract][Full Text] [Related]
3. [Modulation of TLR9 on anti-tumor immune responses of peripheral blood mononuclear cells from patients with non-small-cell lung cancer].
Ren T; Cai YY; Liang YJ; Jin ML; Guo ZL; Tao MF; He X
Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(17):1168-72. PubMed ID: 18844109
[TBL] [Abstract][Full Text] [Related]
4. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
5. Single-cell mass cytometric analysis of peripheral immunity and multiplex plasma marker profiling of non-small cell lung cancer patients receiving PD-1 targeting immune checkpoint inhibitors in comparison with platinum-based chemotherapy.
Neuperger P; Szalontai K; Gémes N; Balog JÁ; Tiszlavicz L; Furák J; Lázár G; Puskás LG; Szebeni GJ
Front Immunol; 2023; 14():1243233. PubMed ID: 37901220
[TBL] [Abstract][Full Text] [Related]
6. OMIP-099: 31-color spectral flow cytometry panel to investigate the steady-state phenotype of human T cells.
Zacharias ZR; Houtman JCD
Cytometry A; 2024 Jan; 105(1):10-15. PubMed ID: 37814476
[TBL] [Abstract][Full Text] [Related]
7. Non-small Cell Lung Cancer Cells Modulate the Development of Human CD1c
Lu Y; Xu W; Gu Y; Chang X; Wei G; Rong Z; Qin L; Chen X; Zhou F
Front Immunol; 2019; 10():2829. PubMed ID: 31921114
[TBL] [Abstract][Full Text] [Related]
8. Dynamic evaluation of blood immune cells predictive of response to immune checkpoint inhibitors in NSCLC by multicolor spectrum flow cytometry.
Ma W; Wei S; Long S; Tian EC; McLaughlin B; Jaimes M; Montoya DJ; Viswanath VR; Chien J; Zhang Q; Van Dyke JE; Chen S; Li T
Front Immunol; 2023; 14():1206631. PubMed ID: 37638022
[TBL] [Abstract][Full Text] [Related]
9. Clinical applications of monitoring immune status with 90 immune cell subsets in human whole blood by 10-color flow cytometry.
Wang W; Li H; Zhang L; Jiang W; Shen L; Fan G
Int J Lab Hematol; 2021 Oct; 43(5):1132-1144. PubMed ID: 33870648
[TBL] [Abstract][Full Text] [Related]
10. OMIP-94: Twenty-four-color (thirty-marker) panel for deep immunophenotyping of immune cells in human peripheral blood.
Pierzchalski A; Zenclussen AC; Herberth G
Cytometry A; 2023 Sep; 103(9):695-702. PubMed ID: 37254600
[TBL] [Abstract][Full Text] [Related]
11. Isolation and immunophenotyping of mononuclear cells from human lung tissue.
Shimizu T; Fujimori F; Shimaoka Y; Narita J; Takada T; Tajima S; Moriyama H; Terada M; Suzuki E; Gejyo F
Intern Med; 2007; 46(4):163-9. PubMed ID: 17301510
[TBL] [Abstract][Full Text] [Related]
12. Immune Cell Composition in Human Non-small Cell Lung Cancer.
Stankovic B; Bjørhovde HAK; Skarshaug R; Aamodt H; Frafjord A; Müller E; Hammarström C; Beraki K; Bækkevold ES; Woldbæk PR; Helland Å; Brustugun OT; Øynebråten I; Corthay A
Front Immunol; 2018; 9():3101. PubMed ID: 30774636
[TBL] [Abstract][Full Text] [Related]
13. OMIP-101: 27-color flow cytometry panel for immunophenotyping of major leukocyte populations in fixed whole blood.
Imbratta C; Reid TD; Toefy A; Scriba TJ; Nemes E
Cytometry A; 2024 Mar; 105(3):165-170. PubMed ID: 38343094
[TBL] [Abstract][Full Text] [Related]
14. Interleukin 8 in plasma is an efficacy marker for advanced non-small cell lung cancer treated with hypofractionated radiotherapy and PD-1 blockade.
Kang P; Liu D; Li L; Guo X; Ye Y; Li Y; Jiang Q; Lin S; Yuan Q
Cytokine; 2023 Mar; 163():156133. PubMed ID: 36724715
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of EZH2 Ameliorates Sepsis Acute Lung Injury (SALI) and Non-Small-Cell Lung Cancer (NSCLC) Proliferation through the PD-L1 Pathway.
Wang Z; Guo Z; Wang X; Liao H; Chai Y; Wang Z; Wang Z
Cells; 2022 Dec; 11(24):. PubMed ID: 36552722
[TBL] [Abstract][Full Text] [Related]
16. Functional Heterogeneity of CD4
Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
Front Immunol; 2018; 9():2654. PubMed ID: 30505306
[TBL] [Abstract][Full Text] [Related]
17. OMIP-084: 28-color full spectrum flow cytometry panel for the comprehensive analysis of human γδ T cells.
Barros-Martins J; Bruni E; Fichtner AS; Cornberg M; Prinz I
Cytometry A; 2022 Oct; 101(10):856-861. PubMed ID: 35521651
[TBL] [Abstract][Full Text] [Related]
18. Location of CD39
Koppensteiner L; Mathieson L; Pattle S; Dorward DA; O'Connor R; Akram AR
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37648263
[TBL] [Abstract][Full Text] [Related]
19. Tumor-draining lymph nodes demonstrate a suppressive immunophenotype in patients with non-small cell lung cancer assessed by endobronchial ultrasound-guided transbronchial needle aspiration: A pilot study.
Murthy V; Katzman DP; Tsay JJ; Bessich JL; Michaud GC; Rafeq S; Minehart J; Mangalick K; de Lafaille MAC; Goparaju C; Pass H; Sterman DH
Lung Cancer; 2019 Nov; 137():94-99. PubMed ID: 31563736
[TBL] [Abstract][Full Text] [Related]
20. CD8
Huang B; Liu R; Wang P; Yuan Z; Yang J; Xiong H; Zhang N; Huang Q; Fu X; Sun W; Li L
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32606053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
